About
Momo Vuyisich, PhD is Viome's Founding Chief Science Officer and Head of Clinical Research, and one of the scientists behind the company's core RNA metatranscriptomic platform. He earned his PhD from the University of Utah in RNA biochemistry, then spent more than a decade at Los Alamos National Laboratory developing the technology Viome commercialized. His publication record includes Viome's salivary metatranscriptome cancer-detection work and population-scale metatranscriptomic platform validation.
What to Know
Signature approach
Vuyisich's scientific frame is RNA gene expression as a live readout of biology. At Viome, that means reading active signals from bacteria, viruses, fungi, archaea, and human cells across stool, saliva, and blood, then using the same metatranscriptomic pipeline for wellness reports and CancerDetect.
What sets them apart
- Platform originator. The metatranscriptomics technology Viome commercialized was developed through his Los Alamos work before company launch.
- Published Viome science. His Scholar profile includes the salivary metatranscriptome cancer-detection papers and population-scale metatranscriptomics validation work.
- RNA-first career. His PhD work centered on RNA biochemistry, giving Viome's platform a long scientific through-line.
Expertise
Focus areas
Affiliations
Thought Leadership
Publications
- Multi-omics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes · Microbiome, 2023
- The salivary metatranscriptome as an accurate diagnostic indicator of oral cancer · NPJ Genomic Medicine, 2021
- A robust metatranscriptomic technology for population-scale studies of diet, gut microbiome, and human health · International Journal of Genomics, 2019
- Detecting salivary host and microbiome RNA signature for aiding diagnosis of oral and throat cancer · Oral Oncology, 2023
- Gut microbiome activity contributes to prediction of individual variation in glycemic response in adults · Diabetes Therapy, 2022
- A clinically validated human capillary blood transcriptome test for global systems biology studies · BioTechniques, 2020
Media Appearances
Notable Collaborators
- Naveen Jain · Viome co-founder & CEO — serial entrepreneur (Moon Express, Intelius, Infospace) who funded the LANL-to-Viome platform commercialization
- Guruduth Banavar, PhD · Viome co-founder & Founding CTO — former IBM Research VP and Watson AI lead; co-leads clinical research with Vuyisich and is first author on Viome's salivary metatranscriptome cancer-detection papers
Other specialists at Viome
Directory listings are for informational purposes only. Inclusion does not constitute endorsement. Verify credentials and qualifications independently.